Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery

Abstract

In this prospective, randomized, placebo-controlled clinical trial, ex vivo treatment of lower extremity vein grafts with edifoligide did not confer protection from reintervention for graft failure.

Critical Limb Ischemia: Current Trends and Future Directions

“…While hemodynamic parameters have remained part of subsequent international consensus guidelines on PAD and CLI,7, 8, 21, 22 these strict hemodynamic criteria are often not part of routine use in clinical as well as research practice. As the definitions used to define CLI in clinical reports vary from merely clinical criteria,4 clinical criteria combined with a variety of objective parameters,23 and definitions based on hospital discharge information,24 research reporting on CLI is inherently variable. Recent consensus statements have proposed stricter definitions that include ankle and toe pressures,7, 22 aiming to improve standardized reporting on CLI, which will be discussed in more detail in the last paragraph of this article.…”

“…The underuse of cardioprotective drugs in the PAD population does not seem limited to PAD patients with relatively mild symptoms. The The Project or Ex‐Vivo vein graft Engineering via Transfection III (PREVENTIII) and BASIL‐trial, which included patients with CLI between 2001 and 2003 and 1999 and 2004, respectively, show that 88% and 46% and 54% and 34% were treated with antiplatelet drugs and statins, respectively 4, 23. However, also in the CLI population, adherence to secondary prevention strategies seems to improve over time.…”

Progress and Prospects: Gene Therapy Clinical Trials (Part 1)

“…46 (6) For vein graft stenosis, despite early positive reports, an E2F transcription factor decoy was ineffective in preventing vein graft failure in patients undergoing peripheral bypass (n ¼ 3804). 47 Currently, a phase II WALK trial is addressing the efficacy of AdHIF-1a on peak walking time at 6 months in approximately 300 PAD patients. A HGF-STAT trial is ongoing to assess the efficacy of naked plasmid HGF on tissue perfusion in patients with non-reconstructable critical ischaemia.…”

Desarrollo de un sistema de telemetría para el seguimiento postoperatorio de procedimientos en cirugía vascular: modelo in vitro

“…Estudios recientes han demostrado que la disminución de la función endotelial venosa está relacionada con un aumento de la tasa de fracaso precoz de los injertos venosos en cirugía coronaria (27) . El estudio PREVENT III, que incluyó más de 1400 bypasses infrainguinales, obtuvo una tasa de oclusión precoz del 5% (28) .…”